Table 2.
Phase 2: Treatment-emergent adverse events of any grade and Grade ≥3.
| Event | Tepotinib | |
|---|---|---|
| Any grade | Grade ≥3 | |
| ≥1 adverse event of any cause,a n (%) | 48 (98.0) | 28 (57.1) |
| ≥1 treatment-related adverse event, n (%) | 41 (83.7) | 14 (28.6) |
| Treatment-related adverse event in ≥5% of patients, n (%) | ||
| Peripheral oedema | 19 (38.8) | 3 (6.1) |
| Asthenia | 11 (22.4) | 0 |
| Fatigue | 9 (18.4) | 0 |
| Diarrhoea | 8 (16.3) | 0 |
| Nausea | 7 (14.3) | 0 |
| Ascites | 6 (12.2) | 2 (4.1) |
| Hypoalbuminaemia | 5 (10.2) | 0 |
| Decreased appetite | 4 (8.2) | 0 |
| Vomiting | 4 (8.2) | 0 |
| Blood creatinine increased | 3 (6.1) | 1 (2.0) |
| Lipase increased | 3 (6.1) | 3 (6.1) |
| Pruritus | 3 (6.1) | 0 |
aTreatment-related adverse events are defined as events that occur within the day of first dose of trial treatment, up until 33 days after last dose of treatment.